Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
Mol Cell Endocrinol ; 180(1-2): 169-77, 2001 Jun 30.
Artigo em Inglês | MEDLINE | ID: mdl-11451588

RESUMO

A recent study from our laboratory demonstrated a strong upregulation of activin expression during cutaneous wound healing. To further analyze the role of activin A in skin morphogenesis and wound repair, we generated transgenic mice that overexpress activin A under the control of the keratin 14 promoter. The latter targets expression of transgenes to the basal, proliferating layer of the epidermis. Hetero- as well as homozygous transgenic animals were viable and fertile. However, they were smaller than non-transgenic littermates and they had smaller ears and shorter tails. Histological analysis of their skin revealed dermal hyperthickening, mainly due to the replacement of fatty tissue by connective tissue, and an increase in suprabasal, partially differentiated epidermal layers. After cutaneous injury, a strong enhancement of granulation tissue formation was observed. Furthermore, the extent of re-epithelialization was increased in some of the wounds. These data demonstrate that activin A is a potent stimulator of the wound healing process. Using an in vivo model of local brain injury, we found that activin A also plays a significant role in the early cellular response to neuronal damage. Expression of activin mRNA and protein is markedly upregulated within a few hours of injury. If applied exogenously, recombinant activin A is capable of rescuing neurons from acute cell death. Studying the interaction between bFGF, a well-established neuroprotective agent, which is currently being tested in stroke patients, and activin A, we arrived at the unexpected conclusion that it is the strong induction of activin A by bFGF which endows the latter with its beneficial actions in patients. These findings suggest that the development of substances directly targeting activin expression or receptor binding should offer new possibilities in the acute treatment of stroke and brain trauma.


Assuntos
Ativinas/fisiologia , Encéfalo/fisiologia , Pele/efeitos dos fármacos , Cicatrização/efeitos dos fármacos , Ativinas/metabolismo , Animais , Encéfalo/efeitos dos fármacos , Encéfalo/patologia , Encefalopatias/metabolismo , Encefalopatias/patologia , Lesões Encefálicas/metabolismo , Lesões Encefálicas/fisiopatologia , Humanos , Pele/lesões , Pele/patologia
2.
Nat Med ; 6(7): 812-5, 2000 Jul.
Artigo em Inglês | MEDLINE | ID: mdl-10888932

RESUMO

Exogenous application of neurotrophic growth factors has emerged as a new and particularly promising approach not only to promote functional recovery after acute brain injury but also to protect neurons against the immediate effect of the injury. Among the various growth factors and cytokines studied so far, the neuroprotective and neurotrophic profile of basic fibroblast growth factor (bFGF) is the best documented. Using an animal model of acute excitotoxic brain injury, we report here that the neuroprotective action of bFGF, which is now being tested in stroke patients, depends on the induction of activin A, a member of the transforming growth factor-beta superfamily. Our evidence for this previously unknown mechanism of action of bFGF is that bFGF strongly enhanced lesion-associated induction of activin A; in the presence of the activin-neutralizing protein follistatin, bFGF was no longer capable of rescuing neurons from excitotoxic death; and recombinant activin A exerted a neuroprotective effect by itself. Our data indicate that the development of substances influencing activin expression or receptor binding should offer new ways to fight neuronal loss in ischemic and traumatic brain injury.


Assuntos
Fator 2 de Crescimento de Fibroblastos/uso terapêutico , Substâncias de Crescimento/biossíntese , Inibinas/biossíntese , Ácido Caínico/toxicidade , Fármacos Neuroprotetores/uso terapêutico , Ativinas , Animais , Encéfalo/efeitos dos fármacos , Substâncias de Crescimento/farmacologia , Hipocampo/efeitos dos fármacos , Inibinas/farmacologia , Masculino , Camundongos , Camundongos Endogâmicos C57BL , Neurônios/metabolismo
3.
Neuroreport ; 7(11): 1819-23, 1996 Jul 29.
Artigo em Inglês | MEDLINE | ID: mdl-8905672

RESUMO

We studied the temporal and spatial mRNA expression pattern of activin/inhibin beta A, beta B and alpha subunits after unilateral kainic acid lesions of the hippocampal CA3 region. We found a strikingly increased expression of beta A mRNA in the ipsilateral hippocampus 6-24 h after injury. By contrast, the beta B and alpha mRNAs were expressed at equally low levels in normal and injured hippocampi, suggesting that the beta A transcripts give rise to activin A, but not to activin AB or inhibin. In situ hybridization demonstrated the presence of beta A mRNA in neurones near the site of lesion. Expression of all known types of activin receptors could be demonstrated in normal and injured hippocampi by RT-PCR. These findings suggest a role of activin in brain injury.


Assuntos
Lesões Encefálicas/metabolismo , Hipocampo/metabolismo , Inibinas/metabolismo , Ativinas , Animais , Feminino , Hibridização In Situ , Ácido Caínico/farmacologia , Camundongos , Camundongos Endogâmicos C57BL , RNA Mensageiro/metabolismo
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...